CITIC Securities Jun 2011 - Aug 2011
Intern- Assistant of Investment Researcher
TechAdvantage@IIT Mar 2010 - May 2011
Project Assistant
CITIC Heavy Industries Jun 2009 - Aug 2009
Intern-Engineer Assistant
Education:
Illinois Institute of Technology 2010 - 2012
Master of Science (MS), Finance, General
Henan University of Science and Technology 2009
Bachelor, Engineering
IIT Stuart Business School
Master of Science, Finance
Skills:
Investment Banking Valuation Data Analysis Research Fixed Income Financial Modeling Portfolio Management Bloomberg SPSS Derivatives Corporate Finance Equities
Electrical Engineer, Master's In Electrical Engineering Candidate, Case Western Reserve University
Research Assistant at Case Western Reserve University: Control & Energy Systems Center Lab Cleveland, Ohio
Location:
Cleveland, Ohio
Industry:
Electrical/Electronic Manufacturing
Work:
Case Western Reserve University: Control & Energy Systems Center Lab Cleveland, Ohio - Cleveland/Akron, Ohio Area since Aug 2012
Research Assistant
Education:
Case Western Reserve University 2012 - 2013
Master of Engineering (MEng), Electrical and Electronics Engineering
Abilene Christian University, Abilene, Texas 2009 - 2011
Bachelors of Science Engineering, Engineering Management
South China University of Technology 2006 - 2009
Bachelor of Engineering (B.Eng.), Electrical and Electronics Engineering
Jun 2011 to Aug 2011 Intern- Assistant of Investment ResearcherTechAdvantage@IIT Chicago, IL Mar 2010 to May 2011 Project AssistantCITIC Heavy Industries LuoYang, CN Jun 2009 to Aug 2009 Intern-Engineer Assistant
Education:
IIT Stuart Business School Chicago, IL Aug 2010 to May 2012 Master of Science in FinanceHeNan University of Science and Technology LuoYang, CN Sep 2005 to Jun 2009 Bachelor of Engineering
Skills:
Language: English (Proficient), Mandarin (Native) Software: Matlab, R, AutoCAD, Microsoft Office and Microsoft Visual Studio Certification: Chartered Financial Analyst Level II Candidate
Us Patents
Crystals Of Hepatitis C Virus Helicase Or Fragments Thereof Comprising A Helicase Binding Pocket
Joseph L. Kim - Natick MA, US Kurt Morgenstern - Derry NH, US Paul Caron - Malden MA, US Chao Lin - Brookline MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 39/29 A61K 38/43 G01N 33/53 C12N 9/00
US Classification:
4242281, 435 71, 435183, 514 2, 514 12
Abstract:
The invention relates to the X-ray crystal structure of the hepatitis C virus helicase domain. More specifically, the invention relates to crystallized complexes of HCV helicase and an oligonucleotide, to crystallizable compositions of HCV helicase and an oligonucleotide and to methods of crystallizing an HCV helicase-oligonucleotide complex. The invention further relates to a computer programmed with the structure coordinates of the HCV helicase oligonucleotide binding pocket or the HCV helicase nucleotide triphosphate pocket wherein said computer is capable of displaying a three-dimensional representation of that binding pocket.
Chao Lin - Winchester MA, US Kai Lin - Waltham MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
C12N 7/00 C07H 21/04
US Classification:
4242181, 536 231
Abstract:
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
Chao Lin - Winchester MA, US Kai Lin - Waltham MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
C07H 23/00 C12N 7/00 C12Q 1/70
US Classification:
536 2371, 4353201, 435 691, 4352351, 435 6
Abstract:
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
Combination Therapy For The Treatment Of Hcv Infection
Ann Kwong - Cambridge MA, US Nagraj Mani - Natick MA, US Yi Zhou - Lexington MA, US Chao Lin - Winchester MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A01N 43/04 A61K 31/70
US Classification:
514 49, 514 43, 514 50, 514 51
Abstract:
The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.
The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
Crystallizable Compositions Comprising A Hepatitis C Virus Ns3 Protease Domain/Ns4A Complex
Joseph Kim - Natick MA, US Kurt Morgenstern - Derry NH, US Chao Lin - Cambridge MA, US Ted Fox - Maynard MA, US John Thomson - Belmont MA, US
Assignee:
Vertex Pharmaceuticals, Incorporated
International Classification:
C12Q001/70 C12N009/50 C12N007/00
US Classification:
435/005000, 435/219000, 435/235100
Abstract:
The present invention relates to compositions and crystals of a hepatitis C virus protease in complex with its viral cofactor. This invention also relates to methods of using the structure coordinates of hepatitis C virus protease in complex with a synthetic NS4A to solve the structure of similar or homologous proteins or protein complexes.
Chao Lin - Brookline MA, US Anne Kwong - Cambridge MA, US
International Classification:
C12Q001/68 C12P019/34
US Classification:
435/006000, 435/091200
Abstract:
The present invention provides a method of accurately assaying the amount of nucleic acids in a biological source. According to another embodiment, the present invention provides a method of accurately assaying HCV in a biological source. The present invention also provides a method of simultaneously screening the effect of a plurality of compounds on the replication of a whole or part of a genome of a biological source. The present invention provides a method of simultaneously screening the effect of a plurality of compounds on the replication of the whole or part of the HCV genome in a biological source.
lead author), Robert Scharpf and Paul Winnard. Collaborators from the Virginia Polytechnic Institute and State University are Ivan Akhrymuk (joint study lead author), Kylene Kehn-Hall, Lauren Panny and Amy Smith. Shih-Chao Lin from the National Taiwan Ocean University also contributed to the study.